This Technavio report covers the present scenario and growth prospects of the global neurological biomarkers market for 2016-2020 (base year: 2015). The revenue generated from the sales of neurological biomarkers are considered to estimate the market size.Note: All values are rounded off. Due to rounding off, some totals may not correspond with the sum/computation of the separate figures.This market is classified based on two product types: consumables and services.Based on the indications wherein these biomarkers are used, they are classified as Alzheimer's disease (AD), multiple sclerosis (MS), autism spectrum disorder (ASD),and Parkinson's disease (PD). Biomarkers are used in various applications such as genomics, proteomics, metabolomics, and imaging. Based on the end-users of these biomarkers, they are classified as hospitals, research laboratories, and diagnostic laboratories.The report also focuses on the vendor landscape of manufacturers, which provides new developments and an exclusive analysis about top vendors of the market. In addition, the report focuses on the market as a whole, the major drivers influencing market growth, and the challenges faced by vendors. The influence of key emerging trends on current and future market scenarios are also discussed in this report.

PART 01: Executive summary 6

Highlights 6

PART 02: Scope of the report 7

Market overview 7

Top-vendor offerings 8

PART 03: Market research methodology 10

Research methodology 10

Economic indicators 10

PART 04: Introduction 11

Key market highlights 11

Biomarker assays kits 11

PART 05: Market landscape 13

Market overview 13

Market size and forecast 14

Five forces analysis: 15

PART 06: Market segmentation by indication 16

AD 16

PD 17

ASD 17

MS 17

PART 07: Market segmentation by application 19

Genomics-based biomarkers 19

Proteomics-based biomarkers 20

Metabolomics-based biomarkers 21

Imaging-based biomarkers 22

Emerging application areas 22

PART 08: Market segmentation by services 24

Services 24

PART 09: Market segmentation by end-user 26

Hospitals 26

Diagnostic and research laboratories 26

PART 10: Geographical segmentation 27

Neurological biomarkers market in Americas 28

Neurological biomarkers market in EMEA 30

Neurological biomarkers market in APAC 32

PART 11: Market drivers 34

Increasing low-cost clinical trials in developing

countries 34

Growing personalized medicine for neurological

disorders 34

Increasing focus toward drug discovery applications 35

PART 12: Impact of drivers 36

PART 13: Market challenges 37

Unmet market needs of effective validation of

biomarkers 37

Reproducibility of biomarkers and tests leading to

discrepancies 37

Delay in market launch 38

PART 14: Impact of drivers and challenges 39

PART 15: Market trends 40

Integrated biology approach will be the key focus area 40

Development of novel radiotracers for neuro biomarkers

that aid diagnostic and clinical applications for

diseases 40

Evolution of miRNA 40

PART 16: Vendor landscape 42

Competitive scenario 42

PART 17: Key vendor analysis 45

Geographic presence — Key vendor analysis 45

Myriad RBM 45

Proteome Sciences 49

QIAGEN 53

Thermo Fisher Scientific 59

Other prominent vendors 64

PART 18: Appendix 66

List of abbreviations 66

PART 19: Explore Technavio 67